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The tumor suppressor p53 is the most frequently mutated gene in 
human cancers, mutated in 25–30% of breast cancers. However, 
mutation rates differ according to breast cancer subtype, being 
more prevalent in aggressive estrogen receptor-negative tumors 
and basal-like and HER2-amplified subtypes. This heterogene-
ity suggests that p53 may function differently across breast can-
cer subtypes. We used RNAi-mediated p53 knockdown (KD) 
and antagomir-mediated KD of microRNAs to study how gene 
expression and cellular response to p53 loss differ in luminal 
versus basal-like breast cancer. As expected, p53 loss caused 
downregulation of established p53 targets (e.g. p21 and miR-34 
family) and increased proliferation in both luminal and basal-like 
cell lines. However, some p53-dependent changes were subtype 
specific, including expression of miR-134, miR-146a and miR-
181b. To study the cellular response to miR-146a upregulation 
in p53-impaired basal-like lines, antagomir KD of miR-146a was 
performed. KD of miR-146a caused decreased proliferation and 
increased apoptosis, effectively ablating the effects of p53 loss. 
Furthermore, we found that miR-146a upregulation decreased 
NF-κB expression and downregulated the NF-κB-dependent 
extrinsic apoptotic pathway (including tumor necrosis factor, 
FADD and TRADD) and antagomir-mediated miR-146a KD 
restored expression of these components, suggesting a plausible 
mechanism for miR-146a-dependent cellular responses. These 
findings are relevant to human basal-like tumor progression in 
vivo, since miR-146a is highly expressed in p53 mutant basal-like 
breast cancers. These findings suggest that targeting miR-146a 
expression may have value for altering the aggressiveness of p53 
mutant basal-like tumors.
Introduction
p53 is one of the most frequently mutated genes in human cancers and 
it is mutated in ~25–30% of breast cancers (1–3). In breast cancer, the 
rates of p53 mutations differ significantly depending upon the molec-
ular subtype, with p53 mutations being most frequent in basal-like/
triple negative breast and HER2-amplified cancers (2,4–8). Recently, 
it was reported that 84% of the basal-like breast cancers and 75% of 
the HER2-amplified breast cancers exhibited p53 mutations (3) com-
pared with 12 and 32% in luminal A and luminal B breast cancers, 
respectively. In addition, p53 mutation status has been shown to be 
an important survival/prognostic marker in breast cancer (7,9). The 
variation in p53 mutational status across different molecular subtypes 
exerts functional consequences and selective pressures that are dif-
ferent in luminal and basal-like breast cancers (8,10). Understanding 
the inherent differences in p53 pathway in luminal versus basal-like 
breast cancers could provide a target for development of new treat-
ment strategies.
p53 interacts with microRNAs (miRs) at multiple levels (11). 
MicroRNAs are small non-coding RNAs (19–25 nucleotide long) 
that downregulate gene expression through sequence specific target-
ing of mRNAs, with resulting translational repression or degradation 
of the target mRNA (12). The expression of microRNAs is tissue 
dependent and expression regulates processes such as cell prolifera-
tion, apoptosis and development (13). Dysregulation of microRNA 
expression has been associated with various types of cancer includ-
ing breast cancer (14).
Cross talk between p53 and microRNAs is complex and bidi-
rectional; p53 regulates the expression and maturation of multiple 
microRNAs and the microRNAs, in turn, can regulate the activity 
and function of p53. The regulation of miR-34 family by p53 has 
been reported by numerous groups (15,16). p53 has also been shown 
to regulate the expression of several other microRNAs including 
miR-145 (17), miR-107 (18), miR-192 and miR-215 (19). p53 modu-
lates the maturation of miR-16-1, miR-143, miR-145 and miR-206 
(11). Conversely, several microRNAs regulate the expression and 
functioning of p53 including miR-504 (20), miR-125b (21), miR-
29a, miR-29b and miR-29c (22), miR-34a (23), miR-122 (24) and 
miR-146a (25).
Based on the intricate relationship between p53 status and micro-
RNAs, we hypothesized that the some differences in the p53 path-
way activity in luminal versus basal-like breast cancers might be a 
function of differential microRNA expression. We analyzed basal-
like and luminal breast cancer cell lines for differential expression 
of microRNAs and mRNAs following knockdown (KD) of p53. 
Several miRs were differentially expressed in a p53-dependent 
fashion in luminal versus basal-like cell lines. We evaluated the 
phenotypes that were modulated by these microRNAs and identi-
fied mRNA expression changes that were associated with the loss 
of these microRNAs. Our results show that p53 loss promotes a 
prosurvival pathway in basal-like breast cancer cells, mediated by 
upregulation of miR-146a.
Materials and methods
Cell lines and culture conditions
Four human breast cancer cell lines with wild-type (WT) p53 status were 
employed for the current study: MCF-7 and ZR-75-1 (two luminal cell lines), 
SUM102 (basal-like cell line) and HME-CC (an immortalized human mam-
mary epithelial cell line with basal-like characteristics). Our previous work 
has compared the cellular response of p53 KD cell lines to cell lines and 
tumors with p53 mutations and found these KD cells to be representative 
models of gene expression responses to p53 loss (5). Since a very small 
number of p53 WT basal-like models have been reported, we have included 
HME-CC with basal-like characteristics as an example of basal-like breast 
cancer cell lines. All isogenic pairs of cell lines (e.g. MCF-7 and MCF-7 with 
p53 KD) were provided by Charles Perou based on methods described in 
Troester et al. (5) and were propagated for <6 months prior to experiments. 
The MCF-7 and ZR-75-1 parents and derivatives were grown and maintained 
in RPMI 1640 with l-glutamine (GIBCO) supplemented with 10% fetal 
bovine serum (Sigma) and 50 units/ml penicillin and 50 units/ml streptomycin 
(GIBCO). Breast cancer cell line SUM102 was obtained from Steve Ethier of 
the Karmanos Cancer Center at Wayne State University, Detroit, MI and was 
maintained in HuMEC (Invitrogen). HME-CC cell line was also maintained 
in HuMEC (Invitrogen) as described previously (10). Stable populations of 
isogenic cell lines, corresponding to all four parent cell lines, but expressing 
p53-RNAi, were established (5). All lines were sequenced and shown to be 
free of p53 mutations prior to KD experiments. These p53 KD populations 
were maintained in the same culture conditions as the parent cell populations, 
with growth medium refreshed three times weekly and cells maintained at 
37°C and 5% CO2.
Abbreviations: KD, knockdown; PDT, population doubling time; SAM, 
Significance Analysis of Microarray; TCGA, The Cancer Genome Atlas; TNF, 
tumor necrosis factor; WT, wild-type.
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RNA and microRNA isolation
Cells were harvested 48 h after plating by scraping them in RNA lysis buffer. 
RNeasy mini kit (Qiagen) was used to isolate total RNA from the cells 
and mirVana miRNA Isolation Kit (AM1560; Ambion) was used to isolate 
miRNA. The quantification for total RNA and microRNA was performed 
using a ND-1000 Nanodrop spectrophotometer. Quality of miRNA and mRNA 
was determined by Agilent Bioanalyzer using an RNA 6000 Nano Chip. All 
samples had RNA integrity numbers >9.
Quantitative real-time PCR for miRNA and NF-κB signaling pathway
The miRNA and NF-κB signaling pathways were analyzed by quantitative 
real-time PCR arrays (Human Cancer miRNA PCR Array, MAH-102C, for 
miRNA arrays and Human NFkB Signaling Pathway Array, PAHS-025A, for 
NF-κB pathway arrays) according to manufacturer’s protocol (SA Biosciences) 
on an Applied Biosystems 7900HT Fast PCR machine. These arrays consisted 
of probes for 88 microRNAs and 84 genes, respectively, with each array. In 
addition, these arrays included the assessment of standard endogenous con-
trol genes for normalization (four in microRNA arrays and five in NF-κB 
arrays) and quality control genes (four in microRNA arrays and seven in 
NF-κB arrays). The relative expression values from miRNA and NF-κB PCR 
arrays were obtained by normalizing to the average of control genes present 
on the array (for miRNA) or by normalizing to glyceraldehyde-3-phosphate 
(for NF-κB) and then normalizing the p53 KD cell lines to their parent cell 
lines. Similarly, the relative expression values of SUM102-p53 KD and HME-
CC-p53 KD cell lines with miR-146a-KD were normalized to SUM102-p53 
KD and HME-CC-p53 KD cell lines.
To identify differentially regulated genes between parent and KD cell 
lines (e.g. MCF-7 versus MCF-7 + p53 KD or SUM102 + p53 KD versus 
SUM102 + p53 KD + antagomir-146a), we conducted Significance Analysis 
of Microarray (SAM) analysis on the 1/(Delta Ct) values (since the Ct values 
are inversely related to expression values). The genes that were significant in 
parental cell lines versus p53 KD cell lines were chosen for further analysis 
after antagomir-146a treatment.
Antagomir-mediated microRNA KD and pre-miR (miRNA precursor)-medi-
ated overexpression of miR-146a
Breast cancer cell lines that overexpressed miR-146a were selected for antago-
mir transfection targeted at miR-146a. Only the p53 KD lines of SUM102 
and HME-CC had high miR-146a, but the parent lines were also transfected 
as controls. Antagomirs (miR-146a; AM17000) and standard control oligom-
ers (anti-miR negative control #1; AM17012) were obtained from Applied 
Biosystems. Transfection conditions were optimized by performing the reverse 
transfection procedure as per the manufacturer’s protocol by using four con-
centrations of siPORT NeoFX Transfection Reagent (Part # AM4510; Applied 
Biosystems). The transfection conditions were optimized by measuring the 
reduction in the expression of HMGA with anti-let-7c transfection as recom-
mended by the manufacturer. Optimal transfection was observed with 12 µl 
in SUM102 and its derivative cell lines, whereas in HME-CC and its deriva-
tive cell lines, the optimal concentration was 18 µl. To overexpress miR-146a, 
basal-like breast cancer cell lines (parental), SUM102 and HME-CC, were 
transfected with pre-miR miRNA precursor (miR-146a, PM 10722; Applied 
Biosystems). The reverse transfection procedure was performed utilizing the 
conditions optimized for antagomir transfections above. All pre-miR and 
antagomir transfections were performed in triplicate and were carried out 
according to manufacturer’s protocol, and control transfections consisting of 
transfection reagent (in the absence of antagomir/pre-miR miRNA precursor) 
as well as non-targeting control were set in parallel. Total RNA and miRNA 
were isolated for further analysis after 48 h.
Expression of mature miR-146a after transfection with targeting antagomirs 
and pre-miR precursors was assessed by real-time PCR. The control and trans-
fected samples were reverse transcribed into cDNA using the miScript Reverse 
Transcription Kit (#218061; Qiagen) and real-time PCR was performed using 
the miScript SYBR Green PCR Kit (#218073; Qiagen) according to the manu-
facturer’s instructions. The miScript Assay used to measure the levels of miR-
146a was obtained from Qiagen (#MS00003535); RNU6-2 (#MS00033740; 
Qiagen) was used as an endogenous control. Expression of miR-146a was 
assessed by real-time PCR utilizing an Applied Biosystems 7900HT Fast PCR 
machine (Applied Biosystems).
Protein isolation and western blotting
Cells were harvested from culture by scraping, and protein was isolated and 
quantitated using the BCA Protein Determination Assay (Pierce kit #23225). 
After denaturing the lysates by boiling them with β-mercaptoethanol, 30 mg 
of protein was electrophoresed on a 4–20% Tris–HCl Criterion precast gel 
(Bio-Rad) and transferred to a Hybond-P membrane (Amersham Biosciences) 
by electroblotting. The blots were probed with antibodies against BRCA1 
and BRCA2 (Santa Cruz Biotechnology) and β-actin (Cell Signaling). Blots 
were washed three times for 5 min with Tris-buffered saline supplemented 
with 0.1% Tween and were probed with ECL Anti-Rabbit IgG Horseradish 
Peroxidase-Linked Whole Antibody (Amersham GE Healthcare). Blots were 
rewashed, and chemiluminescence was used to enhance the detection by uti-
lizing western blotting detection system (Amersham-GE Healthcare). Using 
Image J software, pixel intensity was used to measure the BRCA1, BRCA2 
and β-actin protein bands. Relative BRCA1 and BRCA2 protein concentra-
tions were quantified by dividing the pixel intensity of BRCA1 and BRCA2 
bands with the intensity of the β-actin protein band.
Whole genome microarrays
RNA was isolated, quantified and tested for quality as described above. 
Parental cell lines and their p53 derivative cell lines were run in duplicate (two 
independent experiments) on human whole genome 244K custom microarray 
slides (Agilent) according to the manufacturer’s protocol. Cy3-labeled refer-
ence was Stratagene Universal Human Reference spiked 1:1000 with MCF-7 
RNA and 1:1000 with ME16C RNA. Cy-5-labeled cDNAs were made from 
all experimental samples (SUM102, HME-CC, MCF-7, and ZR-75-1 and p53 
KD cell lines). Labeled cDNAs were prepared using the Agilent QuickAmp 
protocol and were hybridized to arrays overnight and then washed and scanned 
on an Agilent G2505C microarray scanner. All array data are available through 
the Gene Expression Omnibus (GSE pending).
Microarray data were Lowess normalized and probes with >70% good data 
(signal >10 dpi in both channels) were selected for further analysis. Missing 
data were imputed using k-nearest neighbors’ imputation (with k  =  10). 
Duplicate probes were collapsed by averaging and the expression of p53 KD 
cell lines was normalized to corresponding parental cell lines. Data normalized 
in this fashion correspond to the log2 of the fold change due to p53 loss. These 
data were then analyzed by two-class SAM to identify p53-dependent genes 
that differ between luminal and basal-like cell lines (two classes: MCF-7-p53 
KD, ZR-75-1-p53 KD or SUM102-p53 KD, HME-CC-p53 KD). One-class 
SAM analysis was also performed to identify the p53-dependent changes that 
were common to all of the cell lines.
Significant genes were evaluated for ontological enrichment using Ingenuity 
Pathway Analysis, with Benjamini–Hochberg (B–H) multiple testing correc-
tion. Significant functions and pathways were defined as those with B–H P 
values <0.05.
Apoptosis assay
Steady state apoptosis levels were assessed in MCF-7, ZR-75-1, SUM102, 
HME-CC cell lines and their p53 KD derivative cell lines (MCF-7-p53 KD, 
ZR-75-1-p53 KD, SUM102-p53 KD and HME-CC-p53 KD). In addition, we 
also assessed steady state apoptosis levels in SUM102, SUM102-p53 KD, 
HME-CC and HME-CC-p53 KD cell lines with miR-146a KD as well as in 
SUM102 and HME-CC cells with miR-146a overexpression. The apoptosis 
levels were assessed utilizing the Caspase-Glo® 3/7 luminescent Assay (Cat# 
G8091; Promega). Cells were plated at 20 000 K per well in cell culture and 
luminometer-compatible white-walled 96-well plates according to manufac-
turer’s protocol. Each sample was plated at least in triplicate. The lumines-
cence of each sample, as well as blank non-plated wells, was measured in 
plate-reading luminometer after 24 h and the readings were background sub-
tracted before the analysis.
Population doubling times
To assess the proliferation rates of the cell lines as a function of p53 and miR-
146a status, we measured population doubling times (PDT). Cells (150 K) of 
each cell line were plated per 100 mm cell culture dish. Cells were counted 
every 24 h for 6 days and three dishes were counted in triplicate each day. PDT 
were calculated using the equation: PDT = 0.693/k, where k is determined 
from the slope of a linear regression equation of the form: ln A(t) = ln A0 + kt.
miR-146a expression analysis in human breast cancers
Previously published datasets from Blenkiron et  al. (26) and The Cancer 
Genome Atlas (TCGA) network (3) were analyzed for expression of miR-146a 
as a function of breast cancer subtype as well as p53 expression status (WT 
versus mutated). Regarding the Blenkiron dataset, the p53 expression status of 
these tumors was kindly provided by Dr C.Caldas, University of Cambridge, 
Cambridge, UK. The breast cancer subtype status was determined by PAM50. 
Based on the availability of subtype and p53 expression status, our final dataset 
included N = 75 tumors that were not classified as normal-like, specifically: 12 
basal-like breast cancers (n = 5 p53 WT; n = 7 p53 MUT), 34 luminal A breast 
cancers (n = 30 p53 WT; n = 4 p53 MUT), 16 HER2 breast cancers (n = 6 p53 
WT; n = 10 p53 MUT) and 13 luminal B breast cancers (n = 5 p53 WT; n = 
8 p53 MUT). The TCGA dataset consisted of N = 628 (n = 409 p53 WT; n = 
219 p53 MUT) tumor samples for which the p53 status was publicly available. 
Specifically there were: 100 basal-like breast cancers (n = 13 p53 WT; n = 87 
p53 MUT), 320 luminal A breast cancers (n = 282 p53 WT; n = 38 p53 MUT), 
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53 HER2 breast cancers (n = 17 p53 WT; n = 36 p53 MUT), 141 luminal B 
breast cancers (n = 87 p53 WT; n = 54 p53 MUT) and 15 normal-like breast 
cancers (n = 10 p53 WT; n = 4 p53 MUT). In a final, ancillary analysis, we fur-
ther culled the master TCGA dataset [N = 577 (n = 409 p53 WT; n = 168 p53 
MUT)] to exclude two individuals with silent p53 mutations and include only 
fully characterized p53 mutation types (splice mutants, frameshift deletions, 
in-frame deletions, non-sense mutations or missense mutations).
For both the Blenkiron and TCGA analyses, miR-146a microarray expres-
sion was extracted and median-centered across all samples. We used analysis 
of variance with 3 or 7 df to test the differences in mean expression by subtype 
(N = 4 groups) or by subtype and p53 status (N = 8 groups). Boxplots were 
generated to visualize the mean miR-146a expression in each group and to 
also detect outliers. One basal-like, p53 mutant sample with very low relative 
expression was removed (ID = 2219) from the Blenkiron dataset because it 
was beyond Q1 - 1.5 times interquartile range of the strata. We further strati-
fied the TCGA basal-like tumors by p53 mutation type to evaluate associations 
between type of mutation and miR-146a. All analyses were completed using 
R version 2.14. In addition, the basal-like breast cancers in the TCGA dataset 
were also classified based on the functional (gene expression-based) mutation 
status as having p53-WT-like or p53 mutant-like mRNA profiles as described 
in Troester et al. (5). After median-centering, mean miR-146a expression was 
estimated for WT-like and mutant-like samples and differences in mean were 
assessed by student T-test. The majority of tumors (N = 77) were functionally 
p53 mutant and only two were p53 WT. We used analysis of variance to test the 
differences in mean expression by p53 status (N = 2 groups) or p53 mutation 
type. The association between WT-like or mutant-like expression and muta-
tion type (splice mutants, frameshift deletions, in-frame deletions, non-sense 
mutations or missense mutations) was assessed among basal-likes using a chi-
square test. Boxplots were generated to visualize the mean miR-146a expres-
sion in each group and to also detect outliers. All analyses were completed 
using R version 2.14.
Results
Effects of p53 loss on transcription (mRNA and miRNA expression) by 
molecular subtype
To better understand the heterogeneity and inherent differences in p53 
signaling across different molecular subtypes of breast cancer, we 
compared mRNA expression and microRNA expression as a function 
of p53 status in a subset of luminal and basal-like breast cancer cell 
lines. We employed a well-established system of well-characterized 
cell lines and their isogenic pairs with stable p53 KD. A panel of four 
cell lines was included (two basal-like SUM102 and HME-CC and 
two luminal MCF-7 and ZR-75-1). We observed that p53 KD signifi-
cantly altered mRNA expression and miRNA expression. Based on 
the PCR-based microRNA arrays, we identified a common response 
shared by all cell lines indicating the miR-34 family, an established 
p53 target, was downregulated in p53 KD cell lines (Supplementary 
Figure 1, available at Carcinogenesis Online). In addition, expression 
of several other microRNAs changed significantly across numerous 
cell lines as a function of p53 status, including miR-133b, let-7f, 
miR-18a, miR-34c-5p, miR-128, miR-215, miR-181c and miR-148a. 
These microRNAs were downregulated in presence of p53 KD in all 
cell lines except in SUM102, where only miR-34c-5p was downregu-
lated and the rest of these microRNAs were upregulated.
Some p53-dependent changes in microRNA expression were sub-
type specific. The miRs that were differentially expressed in luminal 
versus basal-like p53 KD cell lines included miR-134, miR-146a and 
miR-181b (Figure  1A). These three microRNAs were significantly 
upregulated in basal-like cells with p53 KD and significantly down-
regulated in luminal cell lines with p53 KD (Supplementary Table 1, 
available at Carcinogenesis Online). miR-146a was chosen for fur-
ther analysis based on having the most significant fold change among 
these differentially expressed microRNAs.
Consistent with the patterns of microRNA changes and previously 
published literature (5), we observed that mRNA expression asso-
ciated with p53 loss was different for each cell line and cell type. 
However, a gene expression response was again shared by all cell 
lines, including downregulation of established p53 targets (e.g. p21). 
There were also changes that were common to luminal or to basal-like 
lines. Using a two-class SAM (luminal p53 KD and basal-like p53 
KD cell lines’ gene expression data normalized to corresponding WT 
cell lines’ gene expression data), we observed 137 genes to be upregu-
lated (Figure 1B, grey bar) and 36 genes downregulated (Figure 1B, 
yellow bar) in basal-like cell lines with p53 KD, compared with lumi-
nal cell lines with p53 KD. The Ingenuity Pathway Analysis revealed 
several significant canonical pathways and functions associated with 
these clusters. The upregulated cluster was highly enriched for genes 
associated with proliferation of cells, tumorigenesis, cell growth, 
cell death, apoptosis and immune response. On further analysis, the 
genes upregulated in the apoptosis group included numerous genes 
(like ADAM12, BMP6, CYR61, IGFBP1, ITGB3, MCL1, PDGFRB, 
PTGS2, TGFB2 and XAF1) that have been shown to inhibit apop-
tosis in breast cancer. In addition, significant canonical pathways 
associated with upregulated gene cluster included hepatic fibrosis/
hepatic stellate cell activation, eicosanoid signaling, role of cytokines 
in mediating communication, glucocorticoid receptor signaling and 
integrin-linked kinase signaling among other pathways. Among these 
pathways, integrin-linked kinase has been recognized as anti-apop-
totic factor in breast cancer (27).
p53 loss-dependent cellular responses: proliferation and apoptosis
Based on our observation that microRNA and mRNA expression pat-
terns change significantly as a function of p53 loss and are distinct 
in each subtype, we evaluated the cell lines for relevant phenotypic 
changes. Because apoptotic pathways were p53 dependent in basal-
like relative to luminal breast cancers, we employed luminescence-
based caspase assays to assess the apoptosis levels in luminal and 
basal-like cell lines, both WT and in the presence of p53 KD. We 
observed that basal-like cell lines exhibited distinctly higher (4- to 
5-fold) levels of steady state apoptosis compared with luminal cell 
lines (Figure 1C). In addition, p53 KD resulted in a statistically sig-
nificant reduction in apoptosis in basal-like cell lines, whereas lumi-
nal cell lines did not exhibit such significant response (Figure 1C). 
The basal-like cell lines, SUM102 and HME-CC, exhibited 63 
and 41% statistically significant reductions in presence of p53 KD 
(P = 0.000014 and 0.001 in SUM102 and HME-CC cells), in contrast, 
luminal cell lines, MCF-7 and ZR-75-1, exhibited 12 and 17% reduc-
tion with p53 loss (non-statistically significant; P = 0.14 and 0.19) 
(Figure 1C). We also assessed proliferation rates by evaluating PDT. 
We observed that p53 loss resulted in upregulation of proliferation 
in all cell lines as evidenced by a statistically significant decrease in 
PDT (Table I)
miR-146a-dependent cellular responses
Among the differentially expressed microRNAs, miR-146a was 
upregulated with the most significant fold change. To identify the role 
of this microRNA in modulating the p53-dependent changes in breast 
cancer cell lines, we used antagomirs directed against miR-146a. 
Antagomir transfection resulted in significant reduction of expression 
of miR-146a in HME-CC-p53 KD (P = 7.9 × 10−6) and SUM102-p53 
KD (P = 1.3 × 10–6) cells (Figure 2A). The significance values were 
calculated based on two-tailed unpaired t-test. The HME-CC-p53 
KD exhibited 80-fold increase in miR-146a expression compared 
with HME-CC WT, and antagomir transfection resulted in reduction 
of miR-146a expression down to 8-fold levels to those of HME-CC 
WT (Figure 2A). Similarly, SUM102-p53 KD exhibited an 11-fold 
increase in miR-146a expression compared with SUM102 WT and 
antagomir transfection resulted in reduction of miR-146a expression 
to levels comparable to SUM102 WT (Figure 2A). Thus, the antago-
mir effectively suppressed miR-146a expression. In order to evaluate 
the selectivity of miR-146a antagomir, we measured the expression of 
related family member miR-146b and its expression was not signifi-
cantly altered with the KD of miR-146a (P = 0.30 for HME-CC-p53 
KD cells and P = 0.89 for SUM102-p53 KD cells).
Antagomir KD of miR-146a ablated several p53-dependent phe-
notypic changes, including altered PDT and apoptosis levels. miR-
146a KD in basal-like cells with p53 KD resulted in increased PDT 
indicating reduction in proliferating rates (Table I). These changes 
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in PDT were statistically significant for both HME-CC-p53 KD 
and SUM102-p53 KD cell lines (Table I). This change in doubling 
time may be mediated by apoptosis levels, given that we observed 
miR-146a KD led to a statistically significant (two-tailed, unpaired 
t-test) increase in steady state apoptosis levels in basal-like cells 
with p53 KD (Figure 2B). The HME-CC-p53 KD cell line exhibited 
Fig. 1. Basal-like and luminal breast cancers have distinct transcriptional and phenotypic responses to p53 loss. (A) Fold change in the expression of miRNAs in 
p53 KD cells normalized to parent cells based on real-time PCR results with significant differential expression in luminal versus basal-like cells. The bars represent 
real-time PCR results for miR-134 (black), miR-146a (dark gray) and miR-181b (light gray) in p53 KD cells compared to WT control cells (where relative 
quantification = 1). The error bars represent standard error of the mean. All the experiments were done in triplicate (biological replicates). (B) Cluster analysis of 
basal-like and luminal p53 KD cell lines normalized to parent cell lines showing the gene expression differences in different subtypes as a function of p53 status. 
The red dendrogram branch represents basal-like cells and blue branch represents luminal cell lines. The grey bar represents the genes that are upregulated in basal-
like p53 KD cell lines and the yellow bar represents the genes that are downregulated in basal-like p53 KD cell lines relative to luminal p53 KD cells. All the arrays 
were run in duplicate (biological replicates). (C) Apoptosis levels in luminal and basal-like cell lines, parental and in presence of p53 KD. The black bars represent 
steady state apoptosis levels in luminal breast cancer cells and the dark grey bars represent steady state apoptosis levels in basal-like breast cancer cells. The levels 
were measured in terms of relative luminescence units in caspase 3/7 based apoptosis assay. The reductions in apoptosis level with p53 KD (second bar graph) 
were calculated as percentages of the steady state apoptosis levels in corresponding parent cell lines with WT p53 levels. All the experiments were done in triplicate 
(biological replicates) with each experiment containing three technical replicates. The error bars in all graphs represent standard error of the mean.
Table I. PDT expressed in hours for parent cell lines, p53 KD cell lines and p53 KD cell lines treated with antagomirs to miR-146a
Parent/WT P53 KD P valuea p53 KD, miR-146a KD P valueb
PDT (SE) PDT (SE) PDT (SE)
MCF-7 36.8 (1.7) 20.1 (0.2) 0.0006
ZR-75-1 42.3 (1.0) 35.7 (0.7) 0.006
HME-CC 21.3 (0.8) 16.1 (0.2) 0.003 18.9 (0.1) 0.000067
SUM102 26.3 (0.5) 20.1 (0.2) 0.00001 25.6 (0.0) 0.00001
aComparing WT and p53 KD cell lines in a two-tailed, unpaired t-test. SE, Standard error.
bComparing p53 KD and p53 KD-miR-146a KD cell lines in a two-tailed, unpaired t-test.
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Fig. 2. Effects of antagomir-mediated KD of miR-146a expression in basal-like breast cancer cell lines. (A) Antagomir-mediated KD of miR-146a significantly 
decreased miR-146a expression in basal-like cell lines. The black bars represent real-time PCR results for miR-146a in parent cells (where RQ = 1). The dark 
grey bars represent real-time PCR results for miR-146a in p53 KD cells compared to parent cells and the light grey bars represent real-time PCR results for miR-
146a in p53 KD cells in presence of miR-146a KD. (B) Caspase assay in basal-like cell lines: function of p53 and miR-146a. The black bars represent steady 
state apoptosis levels in parent cells; the dark grey bars represent steady state apoptosis levels in p53 KD cells and the light grey bars represent the steady state 
apoptosis levels in p53 KD cells in presence of miR-146a KD. The levels were measured in terms of luminescence units in caspase 3/7 based apoptosis assay. The 
error bars represent standard error of the mean. (C–G) Changes in expression of extrinsic apoptotic pathway/proapoptotic cascade after p53 KD in the presence/
absence of miR-146a KD. The black bars represent real-time PCR results for gene of interest in parent cells (where RQ = 1). The dark grey bars represent real-
time PCR array results for same gene in p53 KD cells compared to parent cells and the light grey bars represent real-time PCR array results for same gene in 
p53 KD cells in presence of miR-146a KD. The graphs represent changes in expression for (C) TRADD, (D) IRAK1, (E) FADD, (F) TNF and (G) NFKBIA. 
The black horizontal bars on the y-axis represent the WT (null value). All of the experiments were done in triplicate. The changes represented were statistically 
significant based on two-tailed unpaired t-test. The error bars represent standard error of the mean.
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a 45% increase in steady state apoptosis levels in presence of miR-
146a KD (P = 0.0095) and SUM102-p53 KD cell line demonstrated 
96% increase in steady state apoptosis levels (P = 2.3 × 10−4), almost 
doubling the rate of apoptosis in SUM102-p53 KD cells (Figure 2B).
Pre-miR miRNA precursor transfection resulted in a statistically 
significant overexpression of miR-146a in HME-CC and SUM102 
cells (Supplementary Figure 2A, available at Carcinogenesis Online). 
Transfections in HME-CC cells resulted in an 135-fold increase 
in miR-146a expression compared with non-transfected HME-
CC cells (P  =  0.000785) (Supplementary Figure  2A, available at 
Carcinogenesis Online) and SUM102 cells demonstrated 60-fold 
increase in miR-146a expression compared with non-transfected 
SUM102 cells (P = 6.55 × 10−4) (Supplementary Figure 2A, available 
at Carcinogenesis Online). To evaluate potential off target effects of 
pre-miR transfection on other miRNAs, we measured the expression 
of the three highly expressed miRNAs, miR-210, miR-181a and miR-
23b, as well the expression of related family member miR-146b. None 
of these were significantly altered by miR-146a overexpression, nor 
was miR-146b. Overexpression of miR-146a in WT basal-like breast 
cancer cells resulted in a statistically significant reduction in steady 
state apoptosis levels compared with non-transfected cells, thus exhib-
iting a phenotype parallel to the one observed in basal-like breast can-
cer cells with p53 KD (and increased expression of miR-146a). In 
association with miR-146a overexpression, the HME-CC cells exhib-
ited a 46% reduction in apoptosis levels (P = 7.9 × 10−5) and SUM102 
cells demonstrated 51% reduction in apoptosis levels (P = 1.0 × 10−6) 
(Supplementary Figure 2B, available at Carcinogenesis Online).
NF-κB-mediated apoptosis via death receptor pathways
To understand the mechanism behind miR-146a-associated prolifera-
tion and apoptosis changes, we performed mechanistic studies. miR-
146a has been implicated in NF-κB signaling, p53 signaling and in 
regulating expression of BRCA1 and BRCA2. We conducted western 
blot experiments to examine the changes in the BRCA1 and BRCA2 
pathway as a function of p53 status but no significant changes were 
observed in basal-like and luminal cell lines with p53 KD (data not 
shown). Using Human NF-κB Signaling Pathway PCR Arrays, we 
analyzed the expression of key genes related to NF-κB-mediated sig-
nal transduction. We observed that 2 of the genes were significantly 
upregulated (including NFKBIA inhibitor of the NF-κB-mediated 
signaling pathway and CSF3) and 15 genes were significantly 
downregulated in basal-like cell lines with p53 KD (Figure  2C–G; 
Supplementary Table 2, available at Carcinogenesis Online). These 
genes included key regulators of the extrinsic apoptotic pathway/
proapoptotic cascade including tumor necrosis factor (TNF), FADD 
and TRADD as well as an established target of miR-146a – IRAK1 
(Figure  2C–G) (28–31). Antagomir-mediated KD of miR-146a in 
basal-like cell lines with p53 KD restored expression of these com-
ponents and reduced the expression of NFKBIA (Figure 2C–G). The 
observed changes in expression were statistically significant based on 
two-tailed unpaired t-test. These changes were not observed in lumi-
nal cell lines with p53 KD, where only two genes were significantly 
upregulated (TNF and IFNB1) (Supplementary Table 2, available at 
Carcinogenesis Online). These results suggest that an alternate sur-
vival pathway exists for basal-like breast cancer cells with p53 loss, 
mediated by upregulation of miR-146 and downregulation of the 
extrinsic apoptotic pathway including TNF, FADD and TRADD.
miR-146a and pre-miR-146a expression in human breast cancers
We analyzed two publicly available primary breast cancer datasets 
for the patterns of expression of miR-146a based on the molecular 
subtype of breast cancer. We have not observed luminal breast cancer 
cell lines to express high levels of miR-146a and across a dataset of 
>700 tumors, luminal breast cancers express low levels of miR-146a. 
Therefore, we evaluated the role of miR-146a in altering phenotypes 
among basal-likes where the high expression is most relevant. In the 
dataset from Blenkiron et al. (26), we observed that the mean expres-
sion of miR-146a expression in basal-like breast cancers is higher 
than the mean expression of miR-146a in other molecular subtypes of 
breast cancer (luminal A, luminal B and HER2+) (F statistic = 3.23, 
df = 3 and 70, P = 0.03) (Figure 3A). Further stratification of these 
results on p53 status show that basal-like, luminal A  and HER2+ 
breast cancers with WT p53 expression exhibit similar levels of miR-
146a (Figure 3B), but basal-like breast cancers with mutations in p53 
expressed significantly higher levels of miR-146a (F statistic = 2.12, 
df = 3 and 66, P = 0.05) (Figure 3B). In contrast to basal-like breast 
cancers, luminal A  and HER2+ cancers with mutated p53 status 
expressed miR-146a at levels below mean levels (Figure 3B). These 
results confirm our cell line observation that miR-146a is uniquely 
upregulated by p53 loss in basal-like breast cancers. Interestingly, 
however, we also observed that luminal B breast cancers with p53 
mutation upregulated miR-146a, which may play a role in the aggres-
siveness of luminal B relative to luminal A breast cancers (Figure 3B).
To confirm these findings in a second dataset, we analyzed data 
from TCGA project (3). Basal-like breast cancers showed higher 
expression of miR-146a relative to other molecular subtypes of breast 
cancer (F statistic = 66.06, df = 3 and 610, P < 0.001) (Figure 3C). 
Given the relative homogeneity of basal-like breast cancers with 
respect to p53, it is not possible to conduct stable analyses of the p53 
dependence of miR-146a expression among basal-like breast cancers. 
However, since different p53 mutations vary in their functional effects 
on the pathway, we stratified analysis of basal-like breast cancers 
based on the mutation type. p53 mutation status was publicly availa-
ble for 66 of 87 basal-like, p53 mutant samples, therefore, 21 samples 
that lacked this information were excluded from stratified analyses. 
There were 33 samples with missense mutation, 13 samples with 
frameshift deletions, 5 samples with in-frame deletions, 2 with splice 
site mutations and 13 with non-sense mutations. Among basal-like 
breast cancers, the few samples with splice site mutations (n = 2) and 
frameshift deletions (n = 13) exhibited the highest levels of expression 
of miR-146a (Supplementary Figure 3A, available at Carcinogenesis 
Online). In addition, we used comprehensive miRNA expression, p53 
sequence and p53 pathway expression from the TCGA to character-
ize samples both with respect to mutation status and p53-dependent 
gene expression (using a published p53-dependent signature (5) as 
a measure of functional status). We observed that the samples with 
p53 mutant-like expression (n = 77) had significantly higher mean 
expression (134.01 versus −168.14 in the two WT-like samples, 
respectively; t = 5.95, df = 33.34, P value = 1.08e-06) of miR-146a 
across basal-like TCGA samples (Figure  3D). Furthermore, among 
basal-like tumors, all tumors with sequence-based mutation evidence 
showed mutant-like expression except for two tumors with missense 
mutations (Supplementary Figure  3B, available at Carcinogenesis 
Online). These mutant tumors with WT-like expression had lower lev-
els of miR-146a, underscoring that all missense mutations do not have 
functional consequences (32). Also, these missense mutations were 
most likely to be associated with WT like gene expression, indicating 
that all missense mutations also do not have functional consequences 
for p53 activity (33). We also analyzed TCGA data for the expres-
sion of precursor of miR-146a (pre-miR-146a) in these samples. We 
observed that the expression pattern of pre-miR-146a parallels the 
expression of miR-146a (Figure 3C; Supplementary Figure 4A, avail-
able at Carcinogenesis Online). In addition, the expression levels of 
pre-miR-146a exhibited a pattern very similar to that of the mature 
miR-146a when stratified based on mutation type (Supplementary 
Figures 3A and 4B, available at Carcinogenesis Online). This sug-
gests that the differential expression of miR-146a occurs at/above the 
level of synthesis of pre-miR-146a rather than as a result of pre-miR 
processing.
Discussion
Clinically, basal-like breast cancers are associated with aggressive 
behavior and poor prognosis. Basal-like breast cancers exhibit high 
proliferative capacity, high mitotic index and high histological grade 
among other aggressive features (6,34,35). These features correlate 
well with the high expression of proliferation genes in this subtype 
of breast cancer (6,35), but our data show an additional feature that is 
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unique to basal-like breast cancers. Basal-like breast cancer cell lines 
in the presence of WT p53 status exhibit distinctly higher steady state 
apoptosis levels in comparison with the steady state apoptosis levels 
seen in luminal breast cancer cell lines (also with WT p53 expression). 
Apoptosis and proliferation may be counterbalanced at steady state in 
WT cells, but when p53 loss occurs, doubling times may decrease due 
to significantly decreased apoptosis. The decrease in apoptosis associ-
ated with loss of WT p53 expression may contribute both to decreased 
doubling times and to the genomic instability that is well documented 
in basal-like breast cancers (6,34,35). In fact, p53 loss may be an early 
event in the natural history of breast cancer(36), and its importance is 
suggested by the observation that >80% of basal-like breast cancers 
exhibit p53 mutations (3).
Our work sought to identify gene expression changes that may 
result from p53 loss and to evaluate how these changes differ in 
basal-like and luminal lines. We observed that established targets 
of p53 (miR-34c-5p) were downregulated in all cell lines with p53 
KD, consistent with previous findings. And while these established 
targets were among the only miRs that changed similarly in all four 
cell lines, we also discovered novel relationships, with miR-146a 
being significantly upregulated by p53 loss in basal-like cells, but not 
luminal cell lines. Some have speculated that microRNAs are strong 
regulators of cellular state (37), and therefore it may not be surprising 
that cell lines with very distinct differentiation status (basals versus 
luminals) have very distinct microRNA profiles. Recent data from the 
TCGA also establish strong genomic differences between luminal and 
basal-like breast cancers, which fundamentally affect regulation of 
both mRNA and microRNA profiles (3). It is important to link these 
genomic changes to changes in cellular phenotype.
This study has specifically linked changes in miR-146a expres-
sion with changes in apoptosis via altered NF-κB signaling. Figure 4 
presents a proposed model for the effects of p53 loss on miR-146a 
expression and NF-κB death receptor signaling. We have established 
several portions of this mechanism here, showing that p53 negatively 
regulates miR-146a expression, and that in turn, miR-146a regulates 
the apoptosis levels through downregulation of extrinsic apoptotic 
pathway. We have shown that upregulation of NFKBIA, an inhibi-
tor of NF-κB signaling, occurs downstream of miR-146a expression. 
While it is not clear whether upregulation of NFKBIA directly inhib-
its extrinsic apoptotic pathway, we were able to modulate expression 
Fig. 3. miR-146a expression in primary tumors. (A) The box plots represent the expression of miR-146a in basal-like, HER2+, luminal A and luminal B subtypes 
of primary breast cancers in the Blenkiron et al. dataset. (B) The box plots represent the expression of miR-146a in basal-like, HER2+, luminal A and luminal B 
subtypes of primary breast cancers stratified by the expression of p53 in the Blenkiron et al. dataset. (C) The box plots represent the expression of miR-146a in 
basal-like, HER2+, luminal A and luminal B subtypes of primary breast cancers stratified by the expression of p53 in TCGA dataset. (D) The box plots represent 
the expression of miR-146a in basal-like breast cancers stratified by the functional mutational status of p53 in TCGA dataset. The solid bars in the middle of 
boxes indicate the median levels of expression.
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of the extrinsic apoptotic pathway by altering miR-146a expression 
showing a causal role for miR-146a in apoptotic signaling. This mech-
anism is also consistent with previous literature, wherein overexpres-
sion of miR-146a in breast cancer cell lines has been shown to cause 
suppression of NF-κB activity (29). In our data, miR-146a down-
regulated the expression of NF-κB pathway members IRAK1 and 
TRAF6 (changes also seen in Taganov study (30) with LPS-IRAK1 
and TRAF6). We also observed significant reduction in expression of 
genes related to NF-κB-mediated signal transduction and upregula-
tion of the NF-κB inhibitor gene in basal-like breast cancer cell lines 
with p53 KD, whereas no such observations were seen in luminal 
breast cancer cell lines. Given the role of these specific NF-κB targets 
in the extrinsic apoptotic pathway/proapoptotic cascade (28,38), these 
data suggest a plausible mechanism for downregulation of apoptosis. 
NF-κB signaling has been shown to promote apoptosis in response to 
specific signals/cell subtypes (28,31).
Other previous research, consistent with our findings, has empha-
sized miR-146a in immune response, cell growth and cancer. miR-
146a was initially identified and linked with innate immune function 
as a modulator of the response to Toll-like receptor ligands and 
cytokines (30); that study in THP-1 cells identified that miR-146a 
contained two binding sites for NF-κB. Recently, miR-146a been 
shown to be one of the miRs associated with lymphocytic infiltra-
tion in breast cancers (39). Links between 146a and PDT are also 
consistent with previous literature; similar to our findings in basal-
like cancers, upregulation of miR-146a has been shown to protect 
human bronchial epithelial cells from apoptosis and to induce cellular 
proliferation (40). Our results differ from some previous literature. 
miR-146a has been shown to bind to BRCA1 and BRCA2 and modu-
late their expression (41). That study documented an inverse relation 
between the levels of miR-146a expression and BRCA1 protein levels 
and modulating the levels of miR-146a by using pre-miR precursor 
transfections led to a reduction in BRCA1 levels (42). While BRCA1 
loss is a feature of basal-like breast cancers (35) and basal-like cell 
lines in this study exhibited higher levels of miR-146a, increases in 
miR-146a did not result in expected reduction in the levels of BRCA1 
or BRCA2. This may be because the WT SUM102 expresses barely 
detectable levels of BRCA1 transcripts (43) in contrast to six of seven 
basal-like cell lines used in the previous study (42) that express more 
substantial levels of BRCA1 transcripts (43). The SUM102 cells, 
and other basal-like breast cancers, may have a preexisting mecha-
nism for silencing/reducing the expression of BRCA1 that are inde-
pendent of p53-dependent miR-146a upregulation or it may be that 
a functional p53 pathway is required for miR-146a-mediated regu-
lation of BRCA1/2 levels. On the other hand, even in tumors with 
no mutations, a functionally null p53 status might exist due to other 
pathway-level genetic or epigenetic alterations (e.g. MDM2 overex-
pression). Future research should resolve how BRCA1 interacts with 
the p53-miR146a axis.
The previous literature, together with our findings, suggests that 
miR-146a may be an important oncogene. A  recent study in breast 
cancer cells showed that miR-146a was significantly upregulated in 
invasive cell lines when compared with normal and less invasive cell 
lines (44). Previous studies have also shown that abnormal expression 
of miR-146a is associated with paradoxical roles as an oncogene or 
a tumor suppressor in different human cancer tissues. This variation 
seems to be context dependent in terms of tissue type as well as sign-
aling networks. miR-146a has been shown to function as an oncogene 
in cervical cancer (45) and anaplastic thyroid carcinoma (46) but as 
a tumor suppressor in pancreatic cancer (47) and gastric cancer (48). 
Within breast cancer, overexpression of miR-146a has been shown 
to be oncogenic by increasing the proliferation of breast cancer cells 
(42) and to function as a tumor suppressor (29) by impairing the inva-
sion and migration capacity when overexpressed in some breast can-
cer cell lines. These observations reconfirm that miRs are not only 
expressed in tissue specific manner but are also a part of the intricate 
network involving direct interactions and cross talks with other genes, 
microRNAs and signaling molecules. In addition, each microRNA 
can have multiple targets and each target can be regulated by multiple 
microRNAs (i.e. signal integration). In our study, we have identified 
an alternate survival pathway exists for basal-like breast cancer cells 
with p53 loss, mediated by upregulation of miR-146a.
Since a vast majority of basal-like breast cancers lack expression 
of WT p53, identifying the patterns associated with increased tumo-
rigenic potential can have significant translational value. Alternate 
splicing is one of the common ways by which human p53 isoforms are 
abnormally expressed in variety of cancers including breast cancers 
(49). In our dataset, the patients with splice mutations (and frameshift 
mutations) seem to have a stronger miR-146a upregulation than the 
patients with other types of p53 mutations. All mutations are not 
equally likely to limit p53 function, as illustrated in Supplementary 
Figure 3B, available at Carcinogenesis Online, where some missense 
mutations fail to exhibit p53 mutant-like gene expression. While the 
specific mechanisms of splice variant influence on miR-146a upregu-
lation are beyond the scope of this paper, it is clear that the conse-
quences of specific p53 mutations vary. Although the sample sizes in 
individual categories are smaller and bear repeating in other datasets, 
the trend supports our in vitro findings (50). Our study identifies miR-
146a as a potential target that may have value for altering the aggres-
siveness of p53 mutant basal-like tumors. Since miRs are relatively 
stable, resistant to RNase degradation and can be isolated and quanti-
fied precisely from tissue, they can be excellent biomarkers to iden-
tify a specific subtype, in this case basal-like breast cancers with p53 
pathway defects. Targeting miR-146a using anti-sense nucleotides (or 
other modalities currently being developed to modulate the expres-
sion of microRNAs) may provide a way of targeting aggressiveness of 
these basal-like breast cancers. However, it is imperative that miRNA-
based treatments are selective and accurate in target delivery in order 
for them to be therapeutically effective as well as to prevent off-target 
effects and toxicity. Further studies should address how modulation 
of miR-146a levels may affect drug response and other biological 
processes.
Supplementary material
Supplementary Tables 1 and 2 and Figures 1–4 can be found at http://
carcin.oxfordjournals.org/
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